Clinical trials: Breast Cancer Risk
Breast Cancer Stage II
Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer
This is an open-label, multicenter international trial in men and women with primary operable HR+/HER2-, ki67≥20%, grade 2 or 3 and stage II breast cancer to evaluate safety and long-term efficacy of a non-chemo treatment in…
- Trial name
- RIBOLARIS (NCT05296746)
- Testing
- Ribociclib (neoadjuvant), Chemotherapy (adjuvant), Ribociclib (adjuvant)
- Where
- 51 sites in France, Portugal and 1 more
- Volunteers
- 1,100 people
- Sponsor
- SOLTI Breast Cancer Research Group
Breast Cancer
Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer
A randomized multi-arm study evaluating the efficacy and safety of nivolumab versus placebo in combination with neoadjuvant (pre-surgery) chemotherapy and adjuvant (post-surgery) endocrine therapy in participants with high-risk…
- Trial name
- CheckMate 7FL (NCT04109066)
- Testing
- nivolumab, paclitaxel (PTX), anthracycline
- Where
- 240 sites in United States, Argentina and 30 more
- Volunteers
- 521 people
- Sponsor
- Bristol-Myers Squibb
Breast Cancer
Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer
Trial for the optimization of risk assessment and therapy success prediction in patients with early breast cancer by the use of biomarkers in advance to therapy decision-making to personalize therapies.
- Trial name
- ADAPT (NCT01781338)
- Testing
- Induction therapy
- Where
- 2 sites in Germany
- Volunteers
- 4,936 people
- Sponsor
- Women's Cancer Study Group GmbH
Breast Cancer
Breast Tissue Study of Breast Diseases Among Women in Hong Kong
Background: The Chinese University of Hong Kong and the National Cancer Institute are conducting a breast tissue study in connection with another study on breast health.
- Trial name
- NCT01885039
- Where
- 2 sites in China
- Volunteers
- 400 people
- Sponsor
- National Cancer Institute (NCI)
Breast Carcinoma
Breast Cancer Screening Adherence for Women at Moderate Risk for Breast Cancer
This study assesses breast cancer screening adherence for women at moderately increased risk for developing breast cancer based on gene mutation status or empiric risk model estimates.
- Trial name
- NCT07076147
- Testing
- Non-Interventional Study
- Where
- 2 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Breast Cancer
UCLA Breast Cancer Survivor Health Promotion Research Study
Pilot randomized controlled parallel group behavior change comparative effectiveness trial involves 30 breast cancer survivors interested in losing excess body fat.
- Trial name
- NCT05113485
- Testing
- Diabetes Prevention Program-based lifestyle change intervention (DPP), Highly Microbiota-Accessible Foods (HMAFs) intervention
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, Los Angeles
Breast Cancer
Women At Risk: The High Risk Breast Cancer Program
The purpose of this study is to increase understanding of women who are at high risk for developing breast cancer. Data from this group will be collected and entered into a registry.
- Trial name
- WAR (NCT01034891)
- Where
- 2 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- New York Presbyterian Hospital
Breast Cancer
Celecoxib in Preventing Breast Cancer in At-Risk Premenopausal Women
RATIONALE: Chemoprevention therapy uses certain drugs to try to prevent the development or recurrence of cancer. Celecoxib may be effective in preventing breast cancer in at-risk women.
- Trial name
- NCT00056082
- Testing
- celecoxib
- Where
- 3 sites in United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- University of Kansas Medical Center
Cancer
Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment
RATIONALE: Caspofungin acetate or amphotericin B liposomal may be effective in preventing or controlling fever and neutropenia caused by chemotherapy, bone marrow transplantation, or peripheral stem cell transplantation.
- Trial name
- NCT00008359
- Testing
- caspofungin acetate, liposomal amphotericin B
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer
Factors Influencing Decision-Making About the Use of Chemoprevention in Women at Increased Risk for Breast Cancer
RATIONALE: Learning about how patients make decisions about using chemoprevention may help doctors plan treatment in which more patients are willing to choose chemoprevention to reduce their breast cancer risk.
- Trial name
- NCT01399359
- Testing
- Counseling session, Questionnaire 1, Questionnaire 2
- Where
- United States
- Volunteers
- 1,023 people
- Sponsor
- NSABP Foundation Inc
Breast Cancer, Health Behavior
Effect of Planned Education on Health Beliefs and Fatalism in Women at High Risk of Breast Cancer
Purpose: This project aims to examine the effects of planned education on health beliefs and fatalism in women at high risk of breast cancer.
- Conditions
- Breast Cancer, Health Behavior, Breast Self-Examination
- Trial name
- NCT06690320
- Testing
- IMPLEMENTATION OF A PLANNED EDUCATION PROGRAM ON HEALTH BELIEF MODEL AND FATUALIST TENDENCIES IN WOMEN AT HIGH RISK OF BREAST CANCER
- Where
- Turkey (Türkiye)
- Volunteers
- 72 people
- Sponsor
- Ege University
Unilateral Breast Cancer
Prevalence of Lymphedema in Valle Del Cauca, Colombia.
This is an epidemiological cross-sectional study aiming to determine the prevalence of lymphedema and the incidence of risk factors in patients diagnosed with unilateral breast cancer in a cohort from 2008 to 2020 in a…
- Trial name
- NCT04987424
- Testing
- Development and validation of Lymphedema levels diagnostic
- Where
- Colombia
- Volunteers
- 367 people
- Sponsor
- Grupo de investigación C.E.R
Leucogen, Ribociclib
the Efficacy of Leucogen in Preventing the Risk of Ribociclib-Associated Neutropenia in Early Breast Cancer
This study is a multicenter, single-arm, open-label Phase II exploratory clinical trial designed to evaluate whether prophylactic use of leucogen can reduce the incidence of Grade 3 or higher neutropenia in early-stage HR+/HER2…
- Conditions
- Leucogen, Ribociclib, Neutropenia (Low White Blood Cell Count), Breast Cancer
- Trial name
- NCT07380646
- Testing
- Treat Regimen
- Where
- China
- Volunteers
- 97 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Breast Cancer
Combination Chemotherapy With or Without Darbepoetin Alfa in Treating Women With Stage III Breast Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00309920
- Testing
- darbepoetin alfa, cyclophosphamide, docetaxel
- Where
- 47 sites in Germany
- Volunteers
- 1,234 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Curative Breast Cancer Surgery, Inflammatory Positive/Negative Status
Ketorolac in Breast Cancer Surgery
Do the use of Ketorolac in one intravenous injection at the moment of the operative incision reduce the number of recurrence in patient with advanced breast cancer without inflammation signs.
- Conditions
- Curative Breast Cancer Surgery, Inflammatory Positive/Negative Status, Pre Surgical Incision Administration
- Trial name
- KBCt (NCT01806259)
- Testing
- Ketorolac 30 mg IV
- Where
- Belgium
- Volunteers
- 203 people
- Sponsor
- Université Catholique de Louvain